Journal Scans
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
Preemptive Therapy Based on Real-Time Qualitative PCR Improves Relapse-Free Survival in APL
D Grimwade, JV Jovanovic, RK Hills, EA Nugent, Y Patel, R Flora, D Diverio, K Jones, H Aslett, E Batson, K Rennie, R Angell, RE Clark, E Solomon, F Lo-Coco, K Wheatley, AK Burnett
Yes
20090506
2009 Jun 6
J Clin Oncol
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
J Clin Oncol. 2009 Jun 6; Epub ahead of print, D Grimwade, JV Jovanovic, RK Hills, EA Nugent, Y Patel, R Flora, D Diverio, K Jones, H Aslett, E Batson, K Rennie, R Angell, RE Clark, E Solomon, F Lo-Coco, K Wheatley, AK Burnett
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Relapse remains an important cause of treatment failure in 10% to 15% of patients with acute promyelocytic leukemia (APL). A potential strategy for reducing the risk of relapse in these patients is preemptive treatment based on serial monitoring of minimal residual disease (MRD). This study showed that sequential MRD monitoring provides an effective approach for predicting relapse and an alternative to use of the standard prognostic marker, white blood cell (WBC) count >10 X 109. Sequential MRD monitoring...
